MRTX2219

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

PRC2 inhibitor

Related drugs:

‹

›

SMARCA4 mutation	Renal Cell Carcinoma	SMARCA4 mutation	Renal Cell Carcinoma	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D
KDM6A mutation	Renal Cell Carcinoma	KDM6A mutation	Renal Cell Carcinoma	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D

Associations
(2)